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1402Objective: Cryopreserved allograft tissue used in the Norwood procedure for infants with hypoplastic left heart
syndrome causes a marked immunologic sensitization that may complicate future heart transplantation. Treatment
of the allograft tissue before implantation may prevent this sensitization. The purpose of this study was to assess
the anti-human leukocyte antigen antibody response to glutaraldehyde-treated allograft tissue used in the repair of
hypoplastic left heart syndrome.
Methods: Since June 2005, the University of Alberta has subjected allograft vascular tissue used in the Norwood
procedure to glutaraldehyde treatment. An observational study was designed to assess whether glutaraldehyde
treatment of the allograft tissue affected subsequent panel reactive antibody after patch implantation. Panel reac-
tive antibodies for class I (human leukocyte antigen-A, B, C) and class II (human leukocyte antigen-DR, DQ)
antibodies were measured 4 months postoperatively using flow cytometry.
Results: Fourteen patients underwent aNorwoodprocedure usingglutaraldehyde-treated allograft tissue.Historical
controls consisted of 12 patients who underwent aNorwood procedure using untreated allograft tissue.At 4months,
infants who had received glutaraldehyde-treated allograft tissue had lower class I panel reactive antibody (7.3%
17.4% [median, 0%] vs 61.9% [median, 73%]  39.9%; P¼ .0005) and class II panel reactive antibody (6.1%
[median, 0%]  22.7% vs 49.3% [median, 63%]  41.9%, P ¼ .001) compared with the historical controls.
Conclusion: Intraoperative glutaraldehyde treatment of allograft tissue used in hypoplastic left heart syndrome
repair prevents the profound immunologic sensitization that occurs in the majority of infants undergoing surgical
palliation. In patients requiring subsequent heart transplantation, this decreases the risk of antibody-mediated re-
jection and increases the likelihood of finding a suitable donor, thus improving access to transplantation. (J Thorac
Cardiovasc Surg 2010;139:1402-8)Although the results of the Norwood operation for hypoplas-
tic left heart syndrome (HLHS) have improved over the past
2 decades, long-term outcomes are still unknown and a pro-
portion of these children will eventually require cardiac
transplantation.1 Human allograft, or ‘‘homograft,’’ tissue
is routinely used for aortic reconstruction during the Nor-
wood procedure. Allosensitization has been identified as
a consequence of allograft tissue use in cardiac surgery.2,3
This sensitization can be measured as panel-reactive anti-
body (PRA), which describes the proportion of potential
donors in a community against whom the patient has pre-
formed antibodies. Outcomes after transplantation in sensi-
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The Journal of Thoracic and Cardiovascular Surreceiving a ‘‘rescue’’ cardiac transplant after palliative
HLHS repair have a survival disadvantage compared with
patients undergoing primary cardiac transplantation for
HLHS. This survival disadvantage is due to allosensitiza-
tion.5 In addition to inferior outcomes, sensitized patients
are subject to longer wait times and higher mortality while
waiting for transplantation. Thus, a method to decrease the
sensitization that results from allograft tissue use is crucial.
Glutaraldehyde is an aldehyde fixative often used in tissue
preservation. Porcine and bovine tissue can be treated with
glutaraldehyde to allow xenotransplantation in the form of
valved conduits. The effective decellularization and tissue-
strengthening properties of glutaraldehyde, as well as its
ability to cross-link antigens, make xenograft tissue resistant
to both immune and nonimmune-mediated destruction.6 We
hypothesized that glutaraldehyde treatment of allograft tis-
sue would have a similar effect. Thus, the purpose of this
current study was to determine whether glutaraldehyde
could prevent the sensitization response induced by expo-
sure to allograft tissue patches used in the repair of HLHS.
MATERIALS AND METHODS
Study Design
An observational cohort study was conducted to compare the effect of
glutaraldehyde treatment of cryopreserved allograft tissue on PRA aftergery c June 2010
Abbreviations and Acronyms
cPRA ¼ calculated panel reactive antibody
HLA ¼ human leukocyte antigen
HLHS ¼ hypoplastic left heart syndrome
PRA ¼ panel reactive antibody
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eratively. The study was approved by the Human Research and Ethics
Board at the University of Alberta. Cryopreserved aortic homografts were
treated separately with glutaraldehyde and stained for class I and II human
leukocyte antigen (HLA) to detect differences in antigen expression before
and after treatment.
Study Cohort
Fourteen infants born with HLHS underwent first-stage palliation (Nor-
wood procedure) involving aortic arch reconstruction using glutaraldehyde-
treated cryopreserved pulmonary artery allograft tissue between June 2005
and June 2007. Before implantation, the valved allografts were treated with
a glutaraldehyde solution and subsequently rinsed in normal saline and fash-
ioned in the shape needed to reconstruct the neo-aorta. Early in the series,
a 2.6% glutaraldehyde solution was used, but this was modified to a 1%
glutaraldehyde solution in 0.9% normal saline. In short, the valved pulmo-
nary artery homograft was thawed and submersed in a 1% glutaraldehyde
solution for 10 minutes in the operating room under sterile technique. A
sponge was often placed inside the lumen of the homograft to help maintain
its shape during fixation. The allografts were then rinsed in 0.9% normal
saline for 10 minutes. The nonvalved portion of the allograft tissue was
then shaped accordingly and implanted into recipients. Thirteen allografts
were provided by the Comprehensive Tissue Center at University of Alberta
(Edmonton, Alberta, Canada), and 1 allograft was provided by Cryolife Inc
(Kennesaw, Ga).7 Peripheral blood samples were collected 4 months after
implantation when the patients returned for second-stage surgery.
Control Cohort
Twelve infants who underwent aortic arch reconstruction (Norwood pro-
cedure) for HLHS at the University of Alberta between February 2003 and
September 2004 (before the use of glutaraldehyde-treated of allograft tissue)
acted as a historical control cohort. These patients were involved in a prior
study at the University of Alberta, and no new blood samples were drawn.2
Historical data from this cohort were used with permission of the authors.
Variables Studied
Preoperative variables that ensured similarity between the 2 groups in-
cluded age, gender, preoperative length of hospitalization, and blood prod-
uct exposure. Perioperative factors included duration of aorta crossclamping
and cardiopulmonary bypass, use of hypothermic circulatory arrest, and
blood product exposure. Postoperative variables included length of stay in
intensive care unit, length of stay in hospital, and blood product exposure.
All infants received cytomegalovirus-negative, leukocyte-depleted blood.
Donor and Recipient Human Leukocyte Antigen
Typing
Donor and recipient class I and II HLA typing was performed by molec-
ular methodology. Recipient DNAwas purified from whole blood using the
QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, Calif). Donor DNA
was purified from blood, and if no blood was available, bone marrow tissue
was collected by the Comprehensive Tissue Center. HLA-A, B, and DR
antigen typing was performed using the low-resolution Micro SSP DNAThe Journal of Thoracic and Cartyping kit (One Lambda, Inc, Canoga Park, Calif). DNA fragments were
separated by agarose gel electrophoresis. HLA antigens were determined
through a combination of One Lambda DNA/LMT software analysis and
manual interpretation of the electrophoresis results.
Human Leukocyte Antigen Antibody Analysis
Screening for anti-HLA antibodies and antibody specificity for class I
and II HLA was performed as previously described.2 In short, the Flow
PRA Screening Test (One Lambda) was used, which involved exposing
patient sera to a mixture of beads coated in class I and II antigens. Bound
antibody was detected with fluorescein-isothiocyanate conjugated anti-
human immunoglobulin-G F[ab’]2 and measured on a FACSCalibur flow
cytometer (BD Biosciences, San Jose, Calif). Samples that were positive
(PRA>5%) were tested for antibody specificity using single-antigen beads
(Catalog FL2HD and FL1HD; One Lambda). Calculated PRA (cPRA)
values were calculated using the United Network for Organ Sharing
cPRA calculator.8,9
Immunohistochemistry of Cryopreserved Allografts
Cryopreserved aortic allografts were separately collected from the Com-
prehensive Tissue Center (Edmonton, AB, Canada). These allografts con-
sisted of stock that was discarded because of expiration or defects
preventing their use clinically. These allografts were procured and stored
identically to clinically used allografts. The vessel wall of the allograft
was cut into 1-cm sections and exposed to glutaraldehyde solutions and
stored in optimal cutting temperature compound at80C. After cryosec-
tioning, residual aldehydes were quenched with 0.1 mol/L glycine. Samples
were then stained using standard immunohistochemistry techniques with bi-
otinylated secondary antibodies, a peroxidase avidin/biotin complex, and
3,3’-diamniobenzidene as the chromogen. Samples were counterstained
with hematoxylin. Class I HLA was detected with anti-HLA ABC (Catalog
311402; BioLegend, San Diego, Calif), and class II HLA was detected with
anti-HLA DR (Catalog 307602; BioLegend).
Statistical Analysis
Statistical analysis was performed using STATA9.1 (StataCorp, College
Station, Tex). Nonparametric tests were used includingWilcoxon rank-sum
test for continuous data and Fisher’s exact test for binomial data. Data are
expressed in mean and standard deviation for parametric data and median
and standard deviation for nonparametric data.RESULTS
Patient demographics and operative information are sum-
marized in Table 1. With the exception of age at surgery and
interval between surgery and PRA measurement, the groups
are well matched. The more recent cohort was slightly older
at the time of the surgery (8.3 4.8 days vs 14.7 9.7 days;
P ¼ .05) with a slightly longer time period between surgery
and PRA measurement (124.7  16.5 days vs 152.4  40.1
days; P¼ .04). This most likely reflects a change in practice
as we have become more comfortable extending the opera-
tive window from the first week of life.
There was a significant decrease in the class I PRA re-
sponse resulting from exposure to the allograft material in
the glutaraldehyde-treated tissue group compared with the
control group (7.3% [median, 0%]  17.4% vs 61.9 [me-
dian, 73%]  39.9%; P ¼ .0005) (Figure 1). There were
only 2 patients (14.2%) who had a class I PRA greater
than 10% compared with 11 patients (83%) in the historicaldiovascular Surgery c Volume 139, Number 6 1403
TABLE 1. Patient characteristics
Variable Control
Glutaraldehyde
group P value
N 12 14
Gender (m) 75% 50% .24
Age at surgery (d) 8.3 14.7 .05
Bypass time (min) 127 111 .45
Aortic crossclamp time (min) 42.6 46.8 .64
Circulatory arrest time (min) 28 23.5 .27
Height (cm) 50.5 51.5 .37
Weight (kg) 3.4 3.3 .81
Blood (units) 7.4 6 .60
Platelet (units) 4.8 2.6 .35
Fresh-frozen plasma (units) 1.3 0.4 .11
Interval between surgery and
PRA (d)
124.7 152.4 .03
PRA, Panel reactive antibody.
TABLE 2. Class I or II panel reactive antibody less than or more than
10%
PRA Control Glutaraldehyde group Total
<10% 1 12 13
>10% 11 2 13
Total 12 14 26
PRA, Panel reactive antibody.
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nificantly decreased class II PRA compared with the histor-
ical cohort (6.1% [median, 0%] 22.7% vs 49% [median,
63%]  41.9%; P ¼ .001). There was only 1 patient (7%)
in the glutaraldehyde-treated patch group who had a class II
PRA more than 10%, whereas there were 9 patients (75%)
in the control group (Figure 1). There was 1 patient who was
positive for both class I and II in the glutaraldehyde-treated
patch group; in contrast, there was only 1 patient in the con-
trol cohort who was negative for both class I and II PRA. A
PRA of more than 10% in either class I or II is considered
clinically significant sensitization.10 By reorganizing the
data into clinically significant and clinically insignificant
PRA based on this value, the effect of glutaraldehyde-
treatment persists (P< .001) (Table 2). cPRA describes
the percentage of donors who would have 1 or more unac-
ceptable antigens for a sensitized recipient. This calculation
is based on previous donor typings and listing potentialFIGURE 1. Box-plot of PRA by group. The median, 25th, and 75th per-
centiles are shown. Outliers are expressed as separate dots outside the upper
fence. PRA, Panel reactive antibody.
1404 The Journal of Thoracic and Cardiovascular Surdonor antigens as unacceptable (Table 3). Using cPRA con-
firms the prevention of a significant sensitization response in
the glutaraldehyde treatment group (65%  37.3% in his-
torical cohort vs 8.9%  26.0% in glutaraldehyde-treated
group; P< .0001). No significant differences in PRA were
detectable between patients who had received grafts treated
with 1% or 2.6% glutaraldehyde solutions.
In an attempt to identify the source of sensitization, anti-
body specificity was analyzed. This confirmed that many of
the antibodies generated were specific for the HLA type of
the donor allograft (Table 3). Equally important was the fail-
ure to generate anti-HLA antibodies in the absence of HLA
mismatch in individuals who were coincidentally HLA-
matched with their donor allograft. Patient 7 had no mis-
matched class I HLA antigens on the untreated allograft
they received and failed to generate any class I antibodies.
Because blood transfusions can contribute to sensitiza-
tion, linear regression analysis was performed to detect a pos-
sible relationship between number of blood unit exposures
and class I and II PRA. There was no identifiable relation-
ship between blood transfusion and PRA (class I PRA:
b ¼1.29, R2 ¼ 0.04, P ¼ .30; class II PRA: b ¼0.60,
R2 ¼ 0.01, P ¼ .62).
There were no adverse outcomes associated with the
treatment of allograft patches with glutaraldehyde before im-
plantation. Incidentally, there was note of subtle patch calci-
fication at the time of the second-stage surgery at 4 months.
Specifically, there was no recurrence of aortic coarctation in
the glutaraldehyde-treated group.
Immunohistochemistry analysis revealed less detectable
HLA on the allograft tissue after glutaraldehyde treatment
(Figure 2). Furthermore, with increased exposure time or
glutaraldehyde concentration, a dose-response relationship
emerged. This is qualitatively expressed in Table 4.DISCUSSION
Implantation of cryopreserved allograft tissue has been
shown to trigger an immune response, despite the previous
assumption that it was immunologically privileged.3 The
immune response elicited could shorten the life of valved
allografts used for valvular replacement.11 Exposure to sin-
gle-donor HLA results in a much broader sensitization than
expected because of the high level of cross-reactivity be-
tween these antigens. Such cross-reactive epitope groups
explain most of the non–donor-directed antibodies found.gery c June 2010
TABLE 3. Donor-recipient human leukocyte antigen mismatch and antibody specificities at 4 months
Patient Antibody specificities Donor-specific antibodies
PRA 4 mo
cPRA%Class I (%) Class II (%)
1 None None 0 0 0
2 A2 A11 A23 A24 A25 A29 A30 A31 A32 A33 A34 A68 B7 B13 B27 B44
B45 B49 B55 B57 B60 DR7 DR9 DR11 DR12 DR13
No donor typing 100 59 98
3 N/A N/A 92 0 N/A
4 A1 A11 A29 B8 B27 B44 B45 DR7 DR9 DR17 A1 A29 B8 B44
DR7 DR17
99 82 72
5 None confirmed None 17 0 N/A
6 A23 A24 B21 (B49 B50) DR13 DR17 DR53 DR103 A24 B50 DR13 60 93 83
7 DR1 DR15 DR1 DR15 0 67 39
8 A2 A11 A23 A24 A25 A26 A30 A68 B57 B65 DR13 DR14 DR17 A2 B14 (65) DR13 65 85 92
9 A3 A11 A30 A31 B13 B35 A3 B35 31 3 53
10 A3 A24 A25 A29 A32 A33 B8 B13 B18 B27 B35 B40 B45 B49 B55 B57
B62 B65 DR1 DR9 DR11 DR13 DR15 DR103
A24 B8 B40
DR1 DR13
98 99 97
11 A1 A3 A11 A23 A24 A25 A31 A32 B27 B49 B52
B57 DR1
A11 B27 DR1 81 15 82
12 A3 A23 A24 A25 A29 A30 A31 A32 A33 A34 A68
B8 B13 B18 B27 B38 B44 B45 B49 B51 B52 B57
B62 B65 DR7 DR9 DR11 DR12 DR13
No donor typing 100 100 99
13* B7 B27 B45 B27 37 0 30
14* A2 A24 B7 B27 DR1 DR 10 DR 11 DR15 DR103 DR51 DR53 A2 B7 DR1 DR15 DR51 57 85 95
PRA, Panel reactive antibody; cPRA, calculated panel reactive antibody. *Glutaraldehyde-treated group. Patients 1 to 12 consist of the historical control cohort and patients 13 and
14 represent the sensitized patients in the glutaraldehyde-treated group.
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HLA-A1, A29, and B27 are donor related. However,
HLA-A11 and HLA-A1 share a public epitope. Similar
cross-reactivity exists among HLA-B27, B49, B52, and
B57. Conversely, in the patient matched for class I antigens,FIGURE 2. Immunohistochemistry of aortic allograft. A, Untreated aortic allo
HLA-ABC. C, Untreated aortic allograft stained for HLA-DR. D, Glutaraldehyd
The Journal of Thoracic and Carthere was no class I PRA response. Blood transfusions are
known to be potentially sensitizing, but we observed no re-
lationship between blood transfusions and PRA in this
study. This is consistent with previous work at the Univer-
sity of Alberta involving a group of infant patients notgraft stained for HLA-ABC. B, Glutaraldehyde-treated allograft stained for
e-treated allograft stained for HLA-DR. Positive staining (arrows).
diovascular Surgery c Volume 139, Number 6 1405
TABLE 4. Effect of different concentrations and exposure times of glutaraldehyde on human leukocyte antigen expression
HLA-ABC HLA-DR
Concentration
Exposure time
Concentration
Exposure time
5 min 10 min 15 min 20 min 5 min 10 min 15 min 20 min
0.25% þ þ þ þ 0.25% þ þ þ þ
0.5% þ þ - - 0.5% þ þ - -
1.0% þ - - - 1.0% þ - - -
2.0% - - - - 2.0% - - - -
HLA, Human leukocyte antigen. ‘‘þ’’ indicates presence of staining and ‘‘-’’ indicates absence of staining.
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sions.2 Whether this is due to the age of the recipients, the
transient nature of the blood transfusion, or the possible
immunomodulating effects of the blood transfusion itself
is unknown.
Allosensitization that occurs in the neonatal period from
allograft tissue persists for at least 8 years, if not indefi-
nitely.12 Transplantation can be used a ‘‘rescue’’ should it
be required during the palliative repair steps of HLHS. Suc-
cessful palliation includes a lifelong risk of Fontan failure.5
In the setting of organ transplantation, a sensitized patient
faces certain disadvantages. The presence of preformed
anti-HLA antibodies is associated with increased rates of
early high-grade rejection and graft vasculopathy.13 As a re-
sult, survival after transplantation is clearly diminished.4
Thus, sensitized patients may be excluded from transplanta-
tion or limited to rarely available HLA-matched local
donors. This is true across different types of organ transplan-
tation. Enormous effort is currently being directed toward
the identification and management of these sensitized pa-
tients.14 PRA values depend on the assay and the HLA panel
used, and therefore variability can be found between cen-
ters.15 The detection of HLA-specific antibodies allows
identification of unacceptable antigens, and a more clinically
relevant ‘‘PRA value’’ can be calculated. The cPRA reflects
the potential availability of an organ, in particular the donor
pool for a given sensitized patient. This calculator is based
on the kidney donor population, but the heart donor pool
may be considerably smaller. cPRA correlates well with
positive crossmatch outcomes.8
Attempts to prevent immune sensitization have been
largely unsuccessful. Intravenous immunoglobulin has
been used with variable success in ‘‘desensitizing’’ proto-
cols to decrease antibody levels to allow renal transplanta-
tion.16 However, when used in the setting of a Norwood
surgery, intravenous immunoglobulin was ineffective at pre-
venting sensitization.17 Although mycophenolic mofetil can
reduce the HLA antibody response after allograft tissue use,
lifelong immunosuppression is undesirable, especially in the
pediatric population.18 Decellularization has been used
repeatedly in animal studies to prevent generation of
donor-specific antibodies.19 Efforts are being made to repo-
pulate such decellularized tissue with host cells, but such1406 The Journal of Thoracic and Cardiovascular Surtechniques await advances in stem cell research. HLA
matching of donor and recipient would theoretically prevent
sensitization as well. Only recently has our local comprehen-
sive tissue center begun HLA typing of tissue donors. Al-
though possible, lack of sufficient allograft donor tissue
would make it difficult to match all patients.
Glutaraldehyde has been used in cardiac surgery for
decades. Xenograft valves are routinely treated with glutar-
aldehyde because it is thought to prevent xenograft
rejection.20 Glutaraldehyde is also used to strengthen autol-
ogous pericardium when it is used for patching cardiac
defects. Cryopreservation alone removes many of the endo-
thelial cells.21 When implanted valved allografts are
removed surgically during subsequent cardiac surgical pro-
cedures, no donor cellular elements remain.22 As shown by
Baskett and colleagues,11 allograft cellular viability may
promote early graft failure. Thus, removal of cellular ele-
ments from these tissue grafts may be desirable. As an alde-
hyde fixative, glutaraldehyde has the potential to decrease
the cellular viability of allograft tissue.
Glutaraldehyde-treated tissue tends to calcify when
placed in vivo. Xenografts undergo anti-calcification treat-
ments such as with a-amino-oleic acid to help minimize
this in the setting of biological valve replacement, yet they
still eventually fail from calcific degeneration.23 Many, if
not most, allograft tissue transplants calcify in the absence
of glutaraldehyde treatment, and this calcification is more
pronounced in young children.24 The enrolled patients
who have returned for the second-stage operative palliation
for HLHS at the University of Alberta have had noticeably
more calcification of the neoaortic patch if it had been treated
intraoperatively with glutaraldehyde. Because the patch ex-
tends to the site of aortic coarctation repair, there is a theo-
retic risk of increased coarctation recurrence after use of
a glutaraldehyde-treated patch. Recurrence of aortic coarcta-
tion does occur after the Norwood procedure regardless of
patch material used; however, we have observed no cases
of re-coarctation in the patients enrolled. It is also possible
to speculate that treatment with glutaraldehyde might reduce
the incidence of coarctation by reducing the recipient
immune response to the patch. Aortic calcification can
complicate reoperative surgery. To date, there has been no
difficulty during cannulation of these aortas at the 4-monthgery c June 2010
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quent Fontan creation.
The immunohistochemistry results suggest that the mech-
anism of action of glutaraldehyde is disruption of the HLA
molecules on the allograft tissue itself. Whether this is
from accelerated cell death, decreased HLA production in
remaining viable cells, or alteration of the HLA complex it-
self is unclear. Aldehyde fixatives cross-link proteins and
frequently mask antigens when used for tissue fixation for
histologic assessment. This antigen ‘‘masking’’ could be
the very mechanism preventing immune sensitization. Anti-
gen retrieval steps during immunohistochemical staining
can be used to reverse this masking. In our immunohisto-
chemistry protocol, fresh-frozen tissue and cryosections
were used after glutaraldehyde treatment to avoid the need
for antigen retrieval. By immunohistochemistry, expression
of both class I and II HLA were absent at a concentration of
1% glutaraldehyde with exposure times of 10 minutes. This
correlates with the observation that there was no difference
in the PRA response between patients with allograft tissue
treated with 1% versus 2.6% glutaraldehyde in our proto-
col. However, the patches treated with 2.6% glutaraldehyde
may be subject to more calcification. Although staining with
a monoclonal antibody cannot replicate the sensitivity of in
vivo anti-HLA antibodies produced in a sensitized recipient,
it does suggest a dose-dependent decrease in the availability
of HLA with glutaraldehyde treatment. Of note, xenografts
are typically treated for many days with glutaraldehyde, in
contrast with the 10-minute treatment used in this study.
There was 1 patient in the treatment group who was a statis-
tical outlier with a very high class I and II PRA. Because glu-
taraldehyde is colorless and odorless, it is possible that this
patient’s allograft was mistakenly not treated with glutaral-
dehyde.
Limitations
Our study has several limitations. Cohort studies can be
subject to bias, and it was deemed impractical to do a ran-
domized clinical trial in this setting. HLHS is an uncommon
lesion even at large referral centers. The allografts used in
this study all consisted of non-valved allograft wall only;
therefore, these results should not be extrapolated to valved
allograft conduits in which valve function needs to be con-
sidered. The effect of tissue treatment was not universal or
absolute in all subjects, suggesting there are other factors
specific to both the recipient and the donor tissue that may
prove to be important. Because of the lack of available donor
lymphocytes, we were unable to assess the cell-mediated im-
mune response and only comment on humoral immune fac-
tors involved. The increased calcification noted in the
glutaraldehyde-treated allograft tissue group was not fully
anticipated and as a result not measured objectively. The cal-
cification of this tissue may continue past the 4-month
follow-up period.The Journal of Thoracic and CarCONCLUSIONS
Treatment of allograft tissue with glutaraldehyde can pre-
vent the sensitization associated with cryopreserved allo-
graft use after neoaortic reconstruction in HLHS surgery.
Glutaraldehyde treatment is easy to perform in the operating
room with few potential disadvantages. This simple tech-
nique has dramatic potential to improve outcomes for these
individuals who require subsequent heart transplantation.References
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